| Title: |
Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. |
| Authors: |
Linxiao Chen, Valentine, Jenny L., Chung-Jr Huang, Endicott, Christine E., Moeller, Tyler D., Rasmussen, Jed A., Fletcher, Joshua R., Boll, Joseph M., Rosenthal, Joseph A., Dobruchowska, Justyna, Zhirui Wang, Heiss, Christian, Azadi, Parastoo, Putnam, David, Trent, M. Stephen, Jones, Bradley D., DeLisa, Matthew P. |
| Source: |
Proceedings of the National Academy of Sciences of the United States of America; 6/28/2016, Vol. 113 Issue 26, pE3609-E3618, 10p |
| Subject Terms: |
VESICLES (Cytology), IMMUNOGLOBULINS, O antigens, GLYCANS, HUMORAL immunity |
| Abstract: |
The O-antigen polysaccharide (O-PS) component of lipopolysaccharides on the surface of gram-negative bacteria is both a virulence factor and a B-cell antigen. Antibodies elicited by O-PS often confer protection against infection; therefore, O-PS glycoconjugate vaccines have proven useful against a number of different pathogenic bacteria. However, conventional methods for natural extraction or chemical synthesis of O-PS are technically demanding, inefficient, and expensive. Here, we describe an alternative methodology for producing glycoconjugate vaccines whereby recombinant O-PS biosynthesis is coordinated with vesiculation in laboratory strains of Escherichia coli to yield glycosylated outer membrane vesicles (glycOMVs) decorated with pathogen-mimetic glycotopes. Using this approach, glycOMVs corresponding to eight different pathogenic bacteria were generated. For example, expression of a 17-kb O-PS gene cluster from the highly virulent Francisella tularensis subsp. tularensis (type A) strain Schu S4 in hypervesiculating E. coli cells yielded glycOMVs that displayed F. tularensis O-PS. Immunization of BALB/c mice with glycOMVs elicited significant titers of O-PS–specific serum IgG antibodies as well as vaginal and bronchoalveolar IgA antibodies. Importantly, glycOMVs significantly prolonged survival upon subsequent challenge with F. tularensis Schu S4 and provided complete protection against challenge with two different F. tularensis subsp. holarctica (type B) live vaccine strains, thereby demonstrating the vaccine potential of glycOMVs. Given the ease with which recombinant glycotopes can be expressed on OMVs, the strategy described here could be readily adapted for developing vaccines against many other bacterial pathogens. [ABSTRACT FROM AUTHOR] |
|
Copyright of Proceedings of the National Academy of Sciences of the United States of America is the property of National Academy of Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
